AstraZeneca PLCAZN
▼ ネガティブ技術関連度
AstraZeneca's SERD camizestrant (Ecamah) failed as a first-line breast cancer treatment in a late-stage trial.
資産への影響 3
Biotech & Genomic Medicine
AstraZeneca PLC
Olema Pharmaceuticals IncOLMA
▼ ネガティブ競争関連度
Olema fell after AstraZeneca's rival SERD camizestrant failed a first-line breast cancer trial, raising doubts about the class and its own palazestrant.
Novartis AGNOVN
± 混在競争関連度
Novartis is only mentioned as Olema's palazestrant collaboration partner; the rival SERD failure's read-through to its Kisqali combo is unclear.